Globally active biopharmaceutical company AstraZeneca has exercised an option to acquire obesity drug startup SixPeaks Bio. In connection with the deal, Lenz & Staehelin represented AstraZeneca, while Walder Wyss advised SixPeaks Bio and its shareholders.